Skip to main content
Premium Trial:

Request an Annual Quote

Sciex CESI 8000 Plus

Sciex has launched the CESI 8000 Plus, a next-generation CESI-MS platform. The new system enables multiple experiments to be generated from as little as 5 mL of starting material. Combining this capability with the multi-segment injection technology, users can process 10 experiments in the time it would normally take to process one, with less than 1 L of material consumed, Sciex said. The system is ideal for experiments with limited samples, including microdialysates, needle biopsies, FFPE archives, and rare circulating tumor cells; or where samples are highly toxic. In addition, the innovation of neutral capillary surfaces further reduces system flow to less than 10 nanoliters/min, the company said. The platform also delivers higher-resolution separations, improved ionization efficiency, and reduced ion suppression. Optional laser-induced fluorescence, diode-array, and selectable wavelength UV detector modules are available, enabling off-line method development.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.